Casdin Capital, LLC Avidity Biosciences, Inc. Transaction History
Casdin Capital, LLC
- $1.16 Billion
- Q4 2024
A detailed history of Casdin Capital, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 2,045,000 shares of RNA stock, worth $60.4 Million. This represents 5.12% of its overall portfolio holdings.
Number of Shares
2,045,000
Previous 2,084,841
1.91%
Holding current value
$60.4 Million
Previous $95.8 Million
37.9%
% of portfolio
5.12%
Previous 7.44%
Shares
5 transactions
Others Institutions Holding RNA
# of Institutions
258Shares Held
108MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$326 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$279 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$255 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$240 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$234 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.54B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...